Trial reportClinical trials (London, England)2025
Precision medicine evaluation of heterogeneity of treatment effect for a time-to-event outcome with application in a trial of Initial treatment for people living with HIV.
Trial report in Clinical trials (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BackgroundEvaluation of heterogeneity of treatment effect among participants in large randomized clinical trials may provide insights as to the value of individualizing clinical decisions. The effect modeling approach to predictive heterogeneity of treatment effect analysis offers a promising framework for heterogeneity of treatment effect estimation by simultaneously considering multiple patient characteristics and their interactions with treatment to predict differences in outcomes between randomized treatments. However, its implementation in clinical research remains limited and so we provide a detailed example of its application in a randomized trial that compared raltegravir-based vs darunavir/ritonavir-based therapy as initial antiretroviral treatments for people living with HIV.MethodsThe heterogeneity of treatment effect analysis used a two-step procedure, in which a working proportional hazards model was first selected to construct an index score for ranking the treatment difference for individuals, and then a second calibration step used a non-parametric kernel approach to estimate the true treatment difference for participants with similar index scores. Sensitivity and supplemental analyses were conducted to evaluate the robustness of the results. We further explored the impact of covariates on heterogeneity of treatment effect and the choice between treatments.ResultsThe heterogeneity of treatment effect analysis showed that while there is a clear trend favoring raltegravir-based therapy over darunavir/ritonavir-based therapy for the vast majority of the target population, there were a small subset of patients, characterized by more advanced HIV disease status, for whom the choice between the two treatments might be equivocal.ConclusionsThrough this example, we illustrate how an exploratory heterogeneity of treatment effect analysis might provide further insights into the comparative efficacy of treatments evaluated in a randomized trial. We also highlight some of the issues in implementing and interpreting effect modeling analyses in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.